Skip to main content

Sang-jun Shin

Yonsei University · Medicine

About the Lab

Professor Sang-jun Shin's research lab focuses on translational oncology and molecular oncology, with a primary emphasis on understanding the molecular mechanisms underlying colorectal and mucosal melanoma progression. The lab investigates biomarkers such as microsatellite instability (MSI), KLF4, E-cadherin, and uPA to improve prognostic prediction and treatment strategies. It also explores innovative therapeutic approaches, including radiotherapy combined with immune checkpoint inhibitors, particularly in aggressive and rare cancers. The lab integrates molecular pathology with clinical outcomes to guide personalized cancer therapy.

colorectal cancermucosal melanomabiomarkersimmunotherapymolecular oncology

Research Overview

Papers
410
Total Citations
9,136
Papers (5y)
138
Primary Field
Medicine

Research Output Trend

Figures are computed from collected data and may differ slightly.

Publications per year (5y)
138total
2022
2023
2024
2025
2026
Citations per year (5y)
2,237total
20222023202420252026

Selected Papers

15
1
Article|167 citations·2016
Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
Chang Gon Kim, Joong Bae Ahn, Minkyu Jung, Seung‐Hoon Beom, Chan Kim, Joo Hoon Kim, Su Jin Heo, Hyung Soon Park, Jee Hung Kim, Nam Kyu Kim, Byung Soh Min, Hoguen Kim
SJR Q1British Journal of CancerOA

BACKGROUND: Among colorectal cancers (CRCs), high-frequency microsatellite instability (MSI-H) is associated with a better prognosis, compared with low-frequency MSI or microsatellite stability (MSI-L/MSS). However, it is unclear whether MSI affects the prognosis of recurrent CRCs. METHODS: This study included 2940 patients with stage I-III CRC who underwent complete resection. The associations of MSI status with recurrence patterns, disease-free survival (DFS), overall survival from diagnosis t

Pathology and Forensic MedicineMedicine
2
Article|133 citations·2023
LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, S.H. Park, Sang Joon Shin, D.E. Castellano Gauna, Giuseppe Fornarini
SJR Q1Annals of OncologyOA
SurgeryMedicine
3
Article|110 citations·2010
Brain metastases from colorectal carcinoma: prognostic factors and outcome
Minkyu Jung, Joong Bae Ahn, Jong Hee Chang, Chang‐Ok Suh, Soojung Hong, Jae Kyung Roh, Sang Joon Shin, Sun Young Rha
SJR Q1Journal of Neuro-OncologyOA
Pulmonary and Respiratory MedicineMedicine
4
Article|60 citations·2016
Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer
Chang Gon Kim, Joong Bae Ahn, Minkyu Jung, Seung‐Hoon Beom, Su Jin Heo, Jee Hung Kim, Young Jin Kim, Nam Kyu Kim, Byung Soh Min, Woong Sub Koom, Hoguen Kim, Yun Ho Roh
SJR Q1Annals of Surgical OncologyOA
OncologyMedicine
5
Article|45 citations·2019
Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients
Hyun Ju Kim, Jee Suk Chang, Mi Ryung Roh, Byung Ho Oh, Kee Yang Chung, Sang Joon Shin, Woong Sub Koom
SJR Q2Frontiers in OncologyOA

<b>Objective:</b> Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy of radiotherapy (RT), especially combined with immune checkpoint inhibitors (ICIs), for this rare melanoma subtype remains unknown. We investigated the reciprocal effect of RT and ICI on mucosal melanoma patients. <b>Materials and Methods:</b> We identified 23 patients with 31 tumors who were treated with RT between July 2008 and February 2017. All patients received RT for

OncologyMedicine
6
Article|39 citations·2011
Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases
Sang Joon Shin, Hong In Yoon, Nam Kyu Kim, Kang Young Lee, Byung Soh Min, Joong Bae Ahn, Ki Chang Keum, Woong Sub Koom
SJR Q1Radiation OncologyOA

BACKGROUND: Choosing the most effective approach for treating rectal cancer with mesorectal fascia (MRF) involvement or closeness and synchronous distant metastases is a current clinical challenge. The aim of this retrospective study was to determine if upfront systemic chemotherapy and short-course radiotherapy (RT) with delayed surgery enables R0 resection. METHODS: Between March 2009 and October 2009, six patients were selected for upfront chemotherapy and short-course RT (5 × 5 Gy) with dela

OncologyMedicine
7
Article|36 citations·2014
High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
Hayoung Lee, Joong Bae Ahn, Sun Young Rha, Hyun Cheol Chung, Kyu Hyun Park, Tae Soo Kim, Nam Kyu Kim, Sang Joon Shin
SJR Q1World Journal of Surgical OncologyOA

BACKGROUND: Krüppel-like factor 4 (KLF4) is involved in many important cellular processes such as growth, development, differentiation, proliferation, and apoptosis. The purpose of this study was to determine the significance of KLF4 in both tumors and normal tissues of patients with colorectal cancer (CRC). METHODS: Between January 2003 and June 2005, 125 patients with CRC receiving treatment at the Yonsei Cancer Center were selected. We examined the mRNA level of the KLF4 gene in primary CRC s

Molecular BiologyBiochemistry, Genetics and Molecular Biology
8
Article|34 citations·2008
Design and Manufacturing of a Model-scale Active Twist Rotor Prototype Blade
Sang Joon Shin, Carlos E. S. Cesnik, W. Keats Wilkie, Matthew L. Wilbur
SJR Q2Journal of Intelligent Material Systems and Structures

The design and manufacturing of an active twist rotor blade for vibration reduction in helicopters are presented. The rotor blade is integrally twisted by direct strain actuation through embedded piezoelectric fiber composite actuators distributed along the span of the blade. Highlights of the analysis formulation used to design this type of active blade are presented. The requirements for the prototype blade, along with the final design results are also presented. Detailed aspects of its manufa

Aerospace EngineeringEngineering
9
Article|33 citations·2005
Expression of E-Cadherin and uPA and their Association with the Prognosis of Pancreatic Cancer
Sang Joon Shin, Kyeong Ok Kim, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Keuk‐Jun Kim, Joon Hyuk Choi, Hong Seok Song
SJR Q2Japanese Journal of Clinical OncologyOA

OBJECTIVE: E-cadherin (ECD) and urokinase plasminogen activator (uPA) have been noted as markers for tumor metastasis and prognosis in several tumors. We thus investigated the relationship between the expression of ECD and uPA and the clinicopathological characteristics in pancreatic cancer. METHODS: The expression of ECD and uPA was evaluated in pancreatic cancer tissues from 53 patients. RESULTS: Among 53 tumor tissues, those from 29 (54.7%) patients showed positive ECD expression and those fr

Cancer ResearchBiochemistry, Genetics and Molecular Biology
10
Article|31 citations·2021
A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.
Sang Joon Shin, Jeeyun Lee, Tae Min Kim, Jin-Soo Kim, Yu Jung Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Dae Ho Lee, Yoon-Hee Hong, Young Su Noh, Song Kim
SJR Q1Journal of Clinical Oncology

3007 Background: Belvarafenib, a potent, selective RAF dimer (type II) inhibitor, exhibits clinical activity in BRAF V600E - and NRAS-mutant (NRASm) melanoma patients. The combination of belvarafenib and cobimetinib more potently and durably suppressed MAPK pathway output and tumor growth than currently approved BRAF/MEK inhibitors in RAS- or RAF-mutant tumor xenograft models. This interim results of phase 1b trial evaluated the safety, tolerability, pharmacokinetics, and anti-tumor activity of

Molecular BiologyBiochemistry, Genetics and Molecular Biology
11
Article|30 citations·2010
Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer
Sang Joon Shin, Nam Kyu Kim, Ki Chang Keum, Ho Geun Kim, Jun Seok Im, Hye Jin Choi, Seung Hyuk Baik, Jae Hee Choen, Hei‐Cheul Jeung, Sun Young Rha, Jae Kyung Roh, Hyun Cheol Chung
SJR Q1Radiotherapy and OncologyOA
OncologyMedicine
12
Article|24 citations·2016
Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors
Hong In Yoon, Woong Sub Koom, Tae Hyung Kim, Joong Bae Ahn, Minkyu Jung, Tae Il Kim, Hoguen Kim, Sang Joon Shin, Nam Kyu Kim
SJR Q1PLoS ONEOA

These findings demonstrated that a strong possibility that upfront chemotherapy and short-course RT with delayed surgery are an effective alternative treatment for LARC with potentially resectable distant metastasis, owing to achievement of pathologic down-staging, R0 resection, and favorable compliance and toxicity, despite the long treatment duration.

OncologyMedicine
13
Article|22 citations·2012
Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study
Ki‐Yeol Kim, In–Ho Cha, Joong Bae Ahn, Nam Kyu Kim, Sun Young Rha, Hyun Cheol Chung, Jae Kyung Roh, Sang Joon Shin
SJR Q1Journal of Surgical OncologyOA

PURPOSE: Adjuvant chemotherapy has been known as a standard treatment for patients with resected colon cancer. However, in elderly colon cancer patients, the characteristics of patients are heterogeneous with regard to life expectancy and comorbidities. Thus, with regard to the effectiveness of adjuvant chemotherapy for colon cancer, it is difficult to extrapolate data of clinical trials from the younger into the older general population. METHODS: Data for 382 elderly colon cancer patients were

OncologyMedicine
14
Article|22 citations·2009
A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer
Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Kyong Soo Park, Dal Hyun Kim, Chin Kim, Hyun Cheol Chung
SJR Q1Investigational New DrugsOA
Molecular BiologyBiochemistry, Genetics and Molecular Biology
15
Article|22 citations·2010
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
Sang Joon Shin, Joong Bae Ahn, Kyong Soo Park, Yoon Jung Lee, Yong Sang Hong, Tae Won Kim, Hye Ryun Kim, Sun Young Rha, Jae Kyung Roh, Dal-Hyun Kim, Chin Kim, Hyun Cheol Chung
SJR Q1Investigational New Drugs
OncologyMedicine

Research Areas

OncologySurgeryPulmonary and Respiratory MedicineMolecular BiologyAerospace EngineeringHepatology

Dive deeper into Sang-jun Shin's research on Nubint

Open this lab's papers in the app to read with AI, summarize, and cite in your writing.